Mosaic Family Wealth LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 38.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 71,356 shares of the biopharmaceutical company’s stock after acquiring an additional 19,658 shares during the period. Pfizer makes up 1.0% of Mosaic Family Wealth LLC’s portfolio, making the stock its 14th largest holding. Mosaic Family Wealth LLC’s holdings in Pfizer were worth $2,548,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Shine Investment Advisory Services Inc. purchased a new stake in Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in Pfizer in the 2nd quarter valued at about $103,000. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at about $120,000. Finally, Private Vista LLC boosted its position in Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 190,933 shares during the period. Institutional investors own 69.74% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price target for the company in a research report on Monday. Morgan Stanley set a $41.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Friday, January 5th. Jefferies Group set a $38.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Finally, Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $38.83.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.61 earnings per share. equities research analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is presently 78.53%.
Pfizer announced that its Board of Directors has approved a share buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 in the last quarter. Company insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.